Filtry
Anthracycline cardiotoxicity – new possibilities of pharmacological cardioprotection and risks of combination with biological targeted anticancer treatment (NT13457)
to reduce risks of anthracycline cardiotoxicity, although data from complex experimental on impact of bortezomib on anthracycline cardiotoxicity development. cardiomyocytes. Furthermore, potential interference wit...
FR - Farmakologie a lékárnická chemie
- 2012 - 2015 •
- 6 320 tis. Kč •
- 6 320 tis. Kč •
- MZ
Řešení projektu: 1. 4. 2012 - 31. 12. 2015
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Roles of oxidative stress and antioxidative systems in antracycline induced chronic cardiotoxicity in adult patients. (NS9774)
Aim of this study is to evaluate the role of oxidative stress ( level of oxidative stress, major antioxidative enzymes´ activity, gene polymorphisms for major antioxidative enzymes ) in anthracycline induced chronic cardiotoxicity i...
FD - Onkologie a hematologie
- 2008 - 2011 •
- 5 397 tis. Kč •
- 5 163 tis. Kč •
- MZ
Řešení projektu: 1. 7. 2008 - 31. 12. 2011
Uznané náklady
Podpora ze státního rozpočtu (96%)
Poskytovatel: Ministerstvo zdravotnictví
Chemical biology approach to study anthracycline cardiotoxicity and pharmacological cardioprotection with focus on topoisomerase II beta (GA21-16195S)
at the use of chemical biology for study of anthracycline cardiotoxity pathophysiologyAnthracyclines (e.g., doxorubicin, daunorubicin) rank among the important anticancer drugs, but their usefulness is limited by risk of t...
Pharmacology and pharmacy
- 2021 - 2023 •
- 10 035 tis. Kč •
- 10 035 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2021 - 31. 12. 2023
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Automonous circulations functions,myocard and cardiorespiratory functions in children and adolescents after malignancy treatment. (NR8006)
Patients treated during childhood for malignancy with cardiotoxical anthracycline treatment are risk group for development of cardiovascular diseases in adulthood. Frequence of anthracycline cardiotoxicity is conne...
FD - Onkologie a hematologie
- 2004 - 2006 •
- 1 378 tis. Kč •
- 1 365 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2004 - 1. 1. 2006
Uznané náklady
Podpora ze státního rozpočtu (99%)
Poskytovatel: Ministerstvo zdravotnictví
Anthracycline-induced DNA damage signaling in the heart implications for cardiotoxicity development and its pharmacological modulations (GA23-06558S)
Cardiotoxicity and heart failure caused by anthracycline anticancer drugs (ANTs, e.g., doxorubicin or daunorubicin) have been recently linked to topoisomerase II beta (TOP2B)-induced DNA damage in the heart. However, the mechanistic...
Pharmacology and pharmacy
- 2023 - 2025 •
- 9 981 tis. Kč •
- 9 810 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2023 - 31. 12. 2025
Uznané náklady
Podpora ze státního rozpočtu (98%)
Poskytovatel: Grantová agentura České republiky
Study of individual topoisomerase II isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines (GA18-08169S)
their cardiotoxicity has been traditionally attributed to intramyocardial free radical formation to anthracyclines and/or catalytic TOP2 ihibitors, synthesis and in vitro and in vivo design of cardioprotective strategies against th...
Pharmacology and pharmacy
- 2018 - 2020 •
- 9 622 tis. Kč •
- 9 622 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2018 - 31. 12. 2020
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Unique isoform-selective topoisomerase II inhibitors as a tool for effective and safe anticancer therapy (LUAUS24335)
anthracycline cardiotoxicity is the catalytic topoisomerase II (TOP2) inhibitor dexrazoxane in vivo against chronic anthracycline cardiotoxicity. In collaboration with a US of anthracycline cardiotoxi...
Organic chemistry
- 2024 - 2027 •
- 11 512 tis. Kč •
- 11 512 tis. Kč •
- MŠMT
Řešení projektu: 1. 3. 2024 - 31. 12. 2027
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo školství, mládeže a tělovýchovy
Myocardial damage induced by anticancer drugs and ischemia-reperfusion new possibilities of pharmacological cardioprotection. (GA305/09/0416)
) and anthracycline (ANT) cardiotoxicity. Recent in vitro data suggested protective potentialCardiotoxicity of anticancer drugs and ischemia-reperfusion (I/R) rank among of pharmacodynamics of cardioprotective effects of DE...
FR - Farmakologie a lékárnická chemie
- 2009 - 2012 •
- 6 276 tis. Kč •
- 6 276 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2009 - 31. 12. 2012
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
New potential cardioprotective agents study of structure-activity relationships in various types of myocardial injury (GA13-15008S)
Cardiotoxicity of anthracycline anticancer drugs and ischemia-reperfusion are among the important causes of myocardial injury that contribute to the increasing cardiovascular morbidity and mortality. By integrating approaches of med...
FR - Farmakologie a lékárnická chemie
- 2013 - 2017 •
- 10 985 tis. Kč •
- 10 985 tis. Kč •
- GA ČR
Řešení projektu: 1. 2. 2013 - 31. 12. 2017
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Effect of polyphenols and chelators on toxicity and effects of anthracyclines and taxanes (NL7567)
effects of polyphenols and chelators on cardiotoxicity of doxorubicin and epirubicin of apoptosis by anthracyclines and mechanisms of apoptosis induction related to p53......
FR - Farmakologie a lékárnická chemie
- 2003 - 2005 •
- 5 395 tis. Kč •
- 2 443 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (45%)
Poskytovatel: Ministerstvo zdravotnictví
- 1 - 10 z 37